DNA

Children’s Hospital Colorado Announces Innovative In-House Whole-Genome Sequencing LabChildren’s Hospital Colorado Announces Innovative In-House Whole-Genome Sequencing Lab

Children’s Hospital Colorado Announces Innovative In-House Whole-Genome Sequencing Lab

Setting the standard through dynamic genomic technology platform, improving patient outcomes AURORA, Colo., March 12, 2025 /PRNewswire/ -- The Children's…

6 days ago
Children’s Hospital Colorado Announces Innovative In-House Whole-Genome Sequencing LabChildren’s Hospital Colorado Announces Innovative In-House Whole-Genome Sequencing Lab

Children’s Hospital Colorado Announces Innovative In-House Whole-Genome Sequencing Lab

Setting the standard through dynamic genomic technology platform, improving patient outcomes AURORA, Colo., March 12, 2025 /PRNewswire/ -- The Children's…

6 days ago
Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical TestingNext-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing

Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing

Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignanciesVANCOUVER, British Columbia, March…

6 days ago
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company…

1 week ago
Glass House Brands to Host Fourth Quarter and Full Year 2024 Conference Call on March 25, 2025Glass House Brands to Host Fourth Quarter and Full Year 2024 Conference Call on March 25, 2025

Glass House Brands to Host Fourth Quarter and Full Year 2024 Conference Call on March 25, 2025

LONG BEACH, Calif. and TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")…

1 week ago
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell LymphomaAdaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the…

1 week ago
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated…

1 week ago
Illumina addresses recent developments in ChinaIllumina addresses recent developments in China

Illumina addresses recent developments in China

Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4.50 SAN DIEGO, March 10, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq:…

1 week ago
Base Molecular Resonance™ Technologies Announces Breakthrough in DNA Signature Detection, Expanding the Boundaries of Quantum Physics TechnologyBase Molecular Resonance™ Technologies Announces Breakthrough in DNA Signature Detection, Expanding the Boundaries of Quantum Physics Technology

Base Molecular Resonance™ Technologies Announces Breakthrough in DNA Signature Detection, Expanding the Boundaries of Quantum Physics Technology

Revolutionizing Law Enforcement, Medical and Military Applications STUART, Fla., March 10, 2025 /PRNewswire/ -- Base Molecular Resonance™ Technologies (BMRT), a…

1 week ago